



Receipt
FILE COPY

I HEREBY CERTIFY THAT THE ABOVE-IDENTIFIED CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.

BY Sara Fromm DATE July 11, 2000

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of	:	
	Douglas Cines <i>et al.</i>	:	Office of Initial Patent Examination
Appln. No.:	09/544,665	:	
Filed:	April 6, 2000	:	
For:	COMPOSITIONS AND METHODS	:	Attorney Docket
	FOR PROMOTING	:	No. 9596-67U1
	INTERNALIZATION AND	:	K1668CO1
	DEGRADATION OF UROKINASE-	:	
	TYPE PLASMINOGEN ACTIVATOR :	:	

RECEIVED

03 2000

TECH CENTER 1600/2900

RECEIVED

AUG 03 2000

TECH CENTER 1600/2900

REQUEST FOR CORRECTED FILING RECEIPT

Attached is the original Filing Receipt for the above-identified patent application.

IN THE CONTINUING DATA SECTION:

Please change the PCT Application date from "10/17/1997" to "10/15/1998".

The line should read: **"THIS APPLICATION IS A CON OF
PCT/US98/21800 10/15/1998"**

Please make this correction and provide us with a Corrected Filing Receipt.

Respectfully submitted,

DOUGLAS CINES ET AL.

July 11, 2000 By: [Signature]
Date

GARY D. COLBY
Registration No. 40,961
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
One Commerce Square
2005 Market Street - 22nd Floor
Philadelphia, PA 19103-7086
Telephone: 215-965-1285
Facsimile: 215-965-1210

GDC/tmf
Enclosure

FILING RECEIPT




OC000000005184586


 UNITED STATES DEPARTMENT OF
COMMERCE
Patent and Trademark Office

 Address: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231


APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/544,665	04/06/2000	1633	0	9596-67U1	8	24	4

000570

 AKIN GUMP STRAUSS HAUER & FELD LLP
22ND FLOOR ONE COMMERCE SQUARE
2005 MARKET STREET
PHILADELPHIA, PA 19103



Date Mailed: 06/19/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 Douglas Cines, Wynnewood, PA ;
Abd Al-Rooof Higazi, Bala Cynwyd, PA ;

Continuing Data as Claimed by Applicant

 THIS APPLICATION IS A CON OF PCT/US98/21800 ^{10/15/1998} ~~10/17/1997~~
WHICH CLAIMS BENEFIT OF 60/062,274 10/17/1997


Foreign Applications

If Required, Foreign Filing License Granted 06/17/2000

** SMALL ENTITY **

Title

 Compositions and methods for promoting internalization and degradation of urokinase-type
plasminogen activator

Preliminary Class

435

RECEIVED

AUG 03 2000

TECH CENTER 10/15/2000

Data entry by : MEREDITH, WANDA

Team : OIPE

Date: 06/19/2000



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

RECEIVED

AUG 03 2000

GRANTED

TECH CENTER 1

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231